1. Anti-angiogenic active immunotherapy: a new approach to cancer treatment

   • Jianping Pan
   • Pengfeng Jin
   • Dieter Kabelitz

   Review 24 January 2008 Pages: 1105 - 1114

2. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

   • Takuya Osada
   • Gabriel Chong
   • Michael A. Morse

   Original Article 10 January 2008 Pages: 1115 - 1124

   

3. Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer

   • Duane H. Hamilton
   • Peter A. Bretscher

   Original Article 10 January 2008 Pages: 1125 - 1136

   

4. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay

   • Sri Vidya Kondadasula
   • Kimberly A. Varker
   • William E. Carson III

   Original Article 10 January 2008 Pages: 1137 - 1149

   

5. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors

   • Alexander L. Rakhmilevich
   • Ilia N. Buhtoiarov
   • Paul M. Sondel

   Original Article 24 January 2008 Pages: 1151 - 1160

   

6. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine

   • Jean-Pierre Couty
   • Anne-Marie Crain
   • Mireille Viguier

   Original Article 07 February 2008 Pages: 1161 - 1171

   

7. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects

   • Mala Chakraborty
   • Alexander Gelbard
   • James W. Hodge

   Original Article 07 February 2008 Pages: 1173 - 1183

   

8. Recognition of naturally processed and ovarian cancer reactive CD8⁺ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1

   • Junko Matsuzaki
   • Feng Qian
   • Kunle Odunsi

   Original Article 06 February 2008 Pages: 1185 - 1195

   

9. TGFβ secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect

   • Claudia Penafuerte
   • Jacques Galipeau

   Original Article 24 January 2008 Pages: 1197 - 1206

   

10. Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma

    • Reinhold Ramoner
    • Andrea Rahm
    • Martin Thurnher

    Original Article 06 March 2008 Pages: 1207 - 1214

    

11. Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response

    • Darja Kanduc
    • Luciana Tessitore
    • Francesco M. Marincola

    Original Article 07 February 2008 Pages: 1215 - 1223

    

12. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390–bisFv(UCHT1)

    • Jung Hee Woo
    • Sarah H. Bour
    • Arthur E. Frankel

    Original Article 07 February 2008 Pages: 1225 - 1239

    

13. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner

    • Peter Hampson
    • Dean Kavanagh
    • G. Ed Rainger

    Original Article 12 February 2008 Pages: 1241 - 1251

    

14. The neoplastically transformed (CD30^hi) Marek’s disease lymphoma cell phenotype most closely resembles T-regulatory cells

    • L. A. Shack
    • J. J. Buza
    • S. C. Burgess

    Original Article 07 February 2008 Pages: 1253 - 1262

    

15. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

    • Andrew D. Simmons
    • Marina Moskalenko
    • Karin Jooss

    Short Communication 31 January 2008 Pages: 1263 - 1270